Stockscreener 앱 받기
3.85
6.78%
-0.28
전일 마감가:
$4.13
열려 있는:
$4.11
하루 거래량:
1.39M
Relative Volume:
0.90
시가총액:
$297.17M
수익:
-
순이익/손실:
$-78.15M
주가수익비율:
-4.4908
EPS:
-0.8573
순현금흐름:
$-68.89M
1주 성능:
-2.53%
1개월 성능:
+11.27%
6개월 성능:
+122.54%
1년 성능:
+11.59%
1일 변동 폭
$3.805
$4.12
1주일 범위
$3.805
$4.255
52주 변동 폭
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
명칭
Eledon Pharmaceuticals Inc
전화
949-238-8090
주소
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.85 | 297.17M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Guggenheim | Buy |
| 2022-05-13 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 개시 | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Sahm
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000 Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Price to earnings forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Price to earnings forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Price to sales forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - Sahm
Eledon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ELDN) - TradingView
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
ELDN Forecast — Price Target — Prediction for 2027 - TradingView
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - BioSpace
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Nigeria
Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN) - The Globe and Mail
NEWSLETTER: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial - Reuters
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney TransplantationSlideshow (NASDAQ:ELDN) 2026-06-22 - Seeking Alpha
Eledon Pharmaceuticals Amends Certificate of Incorporation – Key Changes Filed in 8-K SEC Report - Minichart
Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote - TipRanks
Leerink raises Eledon Pharmaceuticals price target on trial data - Investing.com
Eledon (NASDAQ: ELDN) holders approve share increase and board slate - Stock Titan
Eledon reports Phase 2 BESTOW kidney transplant data - grafa.com
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation - marketscreener.com
Eledon Pharmaceuticals (ELDN) Presents Promising Phase 2 BESTOW Study Data - GuruFocus
Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data - Investing.com South Africa
Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus - marketscreener.com
Eledon reports kidney function benefit for tegoprubart at 18 months - Investing.com
Eledon reports kidney function benefit for tegoprubart at 18 months By Investing.com - Investing.com South Africa
Eledon Presents Long-Term Extension Phase 2 BESTOW Results - GlobeNewswire
Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Nigeria
Eledon Pharma To Present At The American Transplant Congress - RTTNews
Is Eledon Pharmaceuticals (ELDN) outperforming other medical stocks this year? - MSN
Eledon Pharmaceuticals Inc (ELDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Institutional Confidence - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Eledon Pharmaceuticals Inc (ELDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):